Despite the use of other CCR5 blocking therapies such as leronlimab previously showing some efficacy in humans, the FDA does not currently support its use, and it is apparent that targeting of this specific immune axis is insufficient in preventing COVID-19. This evidence concerns the gene CCR5 and COVID-19.